Background
Methods
Ethical approval
Patients
Clinical and CT evaluation
Clinical management
Data collected
NSE and S100B protein measurements
Statistical analysis
Results
Characteristics of patients and comparison according to severity at 6 months
GOS 1–3 | GOS 4–5 |
p
| |
---|---|---|---|
n = 19 | n = 29 | ||
Age, years | 55 ± 12 | 50 ± 10 | 0.14 |
Gender | |||
Women | 11 | 19 | 0.6 |
Men | 8 | 10 | |
SAPS II ± IQR | 34 ± 30 | 20 ± 13 | <0.01 |
GCS ± IQR | 14 ± 6 | 14 ± 2 | 0.01 |
Initial WFNS score, n (%) | 0.02 | ||
1–2 | 6 (32) | 22 (75) | |
3–5 | 13 (68) | 7 (25) | |
Initial Fisher score, n (%) | 0.8 | ||
1–2 | 2 (11) | 4 (14) | |
3–5 | 17 (89) | 25 (86) | |
Aneurism location, n (%) | 0.1 | ||
ACA + AComA | 13 (68) | 17 (58) | |
CA + PComA | 1 (5) | 8 (28) | |
MCA | 2 (11) | 4 (14) | |
Vertebrobasilar system | 3 (16) | 0 | |
Intraventricular hemorrhage, n (%) | 15 (79) | 17 (60) | 0.2 |
Intraparenchymentous hematoma, n (%) | 8 (42) | 6 (20) | 0.1 |
Hydrocephalus, n (%) | 15 (79) | 17 (60) | 0.2 |
Initial neurogenic lung edema, n (%) | 1 (5) | 3 (10) | 0.4 |
Delayed cerebral ischemia, n (%) | 13 (68) | 3 (11) | <0.001 |
Length of stay in ICU Median (range) | 37 (8–136) | 15(3–68) | 0.1 |
Hospital mortality, n (%) | 9 (47) | 0 | <0.001 |
Time course values of S100β and NSE within the first week following SAH in good and poor outcome groups
Threshold of PS100B and NSE for prognosis 6 months after SAH
Logistic regression analysis
Variables | Odds ratio (95 % confidence interval) |
p value |
---|---|---|
SAPS II | 0.934 (0.877–0.994) | 0.03 |
PS100β at day 5 | 0.051 (0.003–1.029) | 0.05 |
NSE at day 7 | 0.936 (0.855–1.025) | 0.15 |
WFNS score | 0.816 (0.093–7.18) | 0.8 |
Discussion
S100β and NSE: prognostic predictors of SAH
Thresholds of S100β and NSE for prognosis
Association of predictors to improve prognosis
Limitations
Conclusions
Key messages
-
Both PS100β and NSE serum concentration were higher in patients with poor than with good prognosis
-
PS100β and NSE values did not normalize in patients with poor prognosis
-
A normal PS100β plasma concentration at day 5 following SAH and a low SAPS II were strongly and independently associated with a good neurological outcome at 6 months